Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/627 |
Resumo: | Introduction: Chronic myeloid leukemia is a clonal myelo-proliferative disorder with a specific cytogenetic abnormality, a product of the translocation between chromosomes 9 and 22, with subsequent production of a protein with altered tyrosine kinase activity. Historical treatments with drugs such as busulfan, hydroxyurea and interferon are now little used because of the emergence of tyrosine kinase inhibitors, whose main representative drug is Imatinib Mesylate. This is a first-line therapy, and it is well tolerated by patients with low risk of severe adverse events. However, in approximately 10 years of use, there is still some concern about the long-term side effects, such as the development of a second malignancy. Objective: To describe the occurrence of multiple neoplasms in a patient with chronic myeloid leukemia. Method: We report a patient with chronic myeloid leukemia for 13 years, who had used hydroxyurea and interferon as prior therapies and has been using imatinib mesylate for 9 years. Results: Two years ago, the patient developed 2 nodules in his left thigh, which were completely resected. Myxoid lipo sarcoma was diagnosed and he underwent radiotherapy. The computed tomography of the abdomen of control at 6 months detected speculated nodule in the mesenchymal fat adjacent to the jejunum/ileum. After exploratory laparotomy and resection were performed, the pathology showed desmoids fibromatosis. Conclusion: A person with a malignant tumor has an increased risk of developing a second cancer, which may occur in patients with chronic myeloid leukemia. This association may be related to the drugs used in its treatment. |
id |
INCA-1_2d49cee92c0db82a456b0d83f50c3042 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/627 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case ReportOcurrencia del Múltiples Neoplasias en Pacientes con Leucemia Mieloide Crónica: Informe de CasoOcorrência de Múltiplas Neoplasias em Paciente Portador de Leucemia Mieloide Crônica: Relato de CasoLeucemia Mielogênica Crônica BCR -ABL PositivaProteínas de Fusão bcr-ablMesilatosInterferonsHidroxiuréiaSegunda Neoplasia PrimáriaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablMesylatesInterferonsHydroxyureaNeoplasms, Second PrimaryLeucemia Mielogenosa Crónica BCR -ABL PositivaProteínas de Fusión bcr-ablMesilatosInterferonesHidroxiureaNeoplasias Primarias SecundariasIntroduction: Chronic myeloid leukemia is a clonal myelo-proliferative disorder with a specific cytogenetic abnormality, a product of the translocation between chromosomes 9 and 22, with subsequent production of a protein with altered tyrosine kinase activity. Historical treatments with drugs such as busulfan, hydroxyurea and interferon are now little used because of the emergence of tyrosine kinase inhibitors, whose main representative drug is Imatinib Mesylate. This is a first-line therapy, and it is well tolerated by patients with low risk of severe adverse events. However, in approximately 10 years of use, there is still some concern about the long-term side effects, such as the development of a second malignancy. Objective: To describe the occurrence of multiple neoplasms in a patient with chronic myeloid leukemia. Method: We report a patient with chronic myeloid leukemia for 13 years, who had used hydroxyurea and interferon as prior therapies and has been using imatinib mesylate for 9 years. Results: Two years ago, the patient developed 2 nodules in his left thigh, which were completely resected. Myxoid lipo sarcoma was diagnosed and he underwent radiotherapy. The computed tomography of the abdomen of control at 6 months detected speculated nodule in the mesenchymal fat adjacent to the jejunum/ileum. After exploratory laparotomy and resection were performed, the pathology showed desmoids fibromatosis. Conclusion: A person with a malignant tumor has an increased risk of developing a second cancer, which may occur in patients with chronic myeloid leukemia. This association may be related to the drugs used in its treatment. Introducción: Leucemia mieloide crónica es un trastorno mieloproliferativa clonal con una anomalía citogenética específica que resulta de la translocación entre los cromosomas 9 y 22 con la consecuente producción de una proteína con actividad tirosina quinasa alterada. Tratamientos históricos con medicinas como busulfán, hidroxiurea e interferón son poco utilizados debido a la aparición de inhibidores de tirosina quinasa, cuyo principal representante es el mesilato de imatinib. Este fármaco es el tratamiento de primera línea para la leucemia mieloide crónica y fue bien tolerado por los pacientes con bajo riesgo de eventos adversos graves. Sin embargo, alrededor de 10 años de uso, sigue habiendo preocupación por efectos adversos a largo plazo, uno de ellos es el desarrollo de tumores malignos secundarios. Objetivo: Describir la ocurrencia de neoplasias multiples en un paciente con leucemia mieloide crónica. Método: Exponemos el caso de un paciente con leucemia mieloide crónica desde hace 13 años, que utilizo hidroxiurea e interferón tratamiento previo y en uso de mesilato de imatinib durante 9 años. Resultados: Hace 2 años, el paciente presentó dos nódulos en el muslo izquierdo, que fueron totalmente seco. Liposarcoma mixoide fue diagnosticado y el paciente fue sometido a radioterapia. La tomografía computarizada del abdomen de control a los 6 meses detectó nódulo especulado en la grasa mesenquimal adyacente yeyuno / íleon. Hecha la laparatomía exploratoria y resección, la anatomía patológica demostró fibromatosis desmoide. Conclusión: El portador del tumor tiene un riesgo mayor de desarrollar una segunda neoplasia, que por lo tanto puede ocurrir en pacientes con leucemia mieloide cronica. Esto puede estar relacionado con los fármacos utilizados en el tratamiento mismo. Introdução: A leucemia mieloide crônica e um distúrbio mieloproliferativo clonal com uma anormalidade citogenética específica, resultante da translocação entre os cromossomos 9 e 22 com consequente produção de uma proteína com atividade tirosina quinase alterada. Tratamentos históricos com drogas como bussulfan, hidroxiureia e interferon passaram a ser pouco utilizados devido ao surgimento dos inibidores de tirosina quinase, cujo principal representante e o mesilato de imatinibe. Esse fármaco é a terapia de primeira linha, sendo bem tolerado pelos pacientes e com baixo risco de eventos adversos severos. Entretanto, com cerca de dez anos de uso, ainda há preocupação com efeitos colaterais em longo prazo, tais como o desenvolvimento de segunda neoplasia. Objetivo: Descrever a ocurrencia de múltiplas neoplasias em um portador de leucemia mieloide crônica. Método: Relata-se o caso de um paciente com leucemia mieloide crônica há 13 anos, tendo utilizado hidroxiureia e interferon como terapias prévias e em uso de mesilato de imatinibe há nove anos. Resultados: Há dois anos, o paciente apresentou dois nódulos em coxa esquerda que foram totalmente ressecados. Diagnosticou-se lipossarcoma mixoide e o paciente foi submetido à radioterapia. A tomografia computadorizada do abdômen de controle aos seis meses detectou nódulo espiculado na gordura mesenquimal adjacente ao jejuno/íleo. Feita laparotomia exploradora e ressecção, o anatomopatológico demonstrou fibromatose desmoide. Conclusão: O portador de tumor maligno tem risco aumentado de desenvolver uma segunda neoplasia, que pode dessa forma ocorrer nos portadores de leucemia mieloide crônica. Essa associação pode estar relacionada aos fármacos usados no tratamento da mesma. INCA2012-06-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRelato de Casoapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/62710.32635/2176-9745.RBC.2012v58n2.627Revista Brasileira de Cancerologia; Vol. 58 No. 2 (2012): Apr./May/June; 251-255Revista Brasileira de Cancerologia; Vol. 58 Núm. 2 (2012): abr./mayo/jun.; 251-255Revista Brasileira de Cancerologia; v. 58 n. 2 (2012): abr./maio/jun. ; 251-2552176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/627/394Castro, Murilo Antunes deCastro, Mariana Antunes de Peleja, Sebastião BerquóBarbosa, Adriana do Prado Tavares, Renato SampaioRoberti, Maria do Rosário Ferrazinfo:eu-repo/semantics/openAccess2021-11-29T20:14:28Zoai:rbc.inca.gov.br:article/627Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:14:28Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report Ocurrencia del Múltiples Neoplasias en Pacientes con Leucemia Mieloide Crónica: Informe de Caso Ocorrência de Múltiplas Neoplasias em Paciente Portador de Leucemia Mieloide Crônica: Relato de Caso |
title |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
spellingShingle |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report Castro, Murilo Antunes de Leucemia Mielogênica Crônica BCR -ABL Positiva Proteínas de Fusão bcr-abl Mesilatos Interferons Hidroxiuréia Segunda Neoplasia Primária Leukemia, Myelogenous, Chronic, BCR-ABL Positive Fusion Proteins, bcr-abl Mesylates Interferons Hydroxyurea Neoplasms, Second Primary Leucemia Mielogenosa Crónica BCR -ABL Positiva Proteínas de Fusión bcr-abl Mesilatos Interferones Hidroxiurea Neoplasias Primarias Secundarias |
title_short |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
title_full |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
title_fullStr |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
title_full_unstemmed |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
title_sort |
Occurrence of Multiple Neoplasms in Patient with Chronic Myeloid Leukemia: Case Report |
author |
Castro, Murilo Antunes de |
author_facet |
Castro, Murilo Antunes de Castro, Mariana Antunes de Peleja, Sebastião Berquó Barbosa, Adriana do Prado Tavares, Renato Sampaio Roberti, Maria do Rosário Ferraz |
author_role |
author |
author2 |
Castro, Mariana Antunes de Peleja, Sebastião Berquó Barbosa, Adriana do Prado Tavares, Renato Sampaio Roberti, Maria do Rosário Ferraz |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Castro, Murilo Antunes de Castro, Mariana Antunes de Peleja, Sebastião Berquó Barbosa, Adriana do Prado Tavares, Renato Sampaio Roberti, Maria do Rosário Ferraz |
dc.subject.por.fl_str_mv |
Leucemia Mielogênica Crônica BCR -ABL Positiva Proteínas de Fusão bcr-abl Mesilatos Interferons Hidroxiuréia Segunda Neoplasia Primária Leukemia, Myelogenous, Chronic, BCR-ABL Positive Fusion Proteins, bcr-abl Mesylates Interferons Hydroxyurea Neoplasms, Second Primary Leucemia Mielogenosa Crónica BCR -ABL Positiva Proteínas de Fusión bcr-abl Mesilatos Interferones Hidroxiurea Neoplasias Primarias Secundarias |
topic |
Leucemia Mielogênica Crônica BCR -ABL Positiva Proteínas de Fusão bcr-abl Mesilatos Interferons Hidroxiuréia Segunda Neoplasia Primária Leukemia, Myelogenous, Chronic, BCR-ABL Positive Fusion Proteins, bcr-abl Mesylates Interferons Hydroxyurea Neoplasms, Second Primary Leucemia Mielogenosa Crónica BCR -ABL Positiva Proteínas de Fusión bcr-abl Mesilatos Interferones Hidroxiurea Neoplasias Primarias Secundarias |
description |
Introduction: Chronic myeloid leukemia is a clonal myelo-proliferative disorder with a specific cytogenetic abnormality, a product of the translocation between chromosomes 9 and 22, with subsequent production of a protein with altered tyrosine kinase activity. Historical treatments with drugs such as busulfan, hydroxyurea and interferon are now little used because of the emergence of tyrosine kinase inhibitors, whose main representative drug is Imatinib Mesylate. This is a first-line therapy, and it is well tolerated by patients with low risk of severe adverse events. However, in approximately 10 years of use, there is still some concern about the long-term side effects, such as the development of a second malignancy. Objective: To describe the occurrence of multiple neoplasms in a patient with chronic myeloid leukemia. Method: We report a patient with chronic myeloid leukemia for 13 years, who had used hydroxyurea and interferon as prior therapies and has been using imatinib mesylate for 9 years. Results: Two years ago, the patient developed 2 nodules in his left thigh, which were completely resected. Myxoid lipo sarcoma was diagnosed and he underwent radiotherapy. The computed tomography of the abdomen of control at 6 months detected speculated nodule in the mesenchymal fat adjacent to the jejunum/ileum. After exploratory laparotomy and resection were performed, the pathology showed desmoids fibromatosis. Conclusion: A person with a malignant tumor has an increased risk of developing a second cancer, which may occur in patients with chronic myeloid leukemia. This association may be related to the drugs used in its treatment. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-06-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Relato de Caso |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/627 10.32635/2176-9745.RBC.2012v58n2.627 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/627 |
identifier_str_mv |
10.32635/2176-9745.RBC.2012v58n2.627 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/627/394 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 58 No. 2 (2012): Apr./May/June; 251-255 Revista Brasileira de Cancerologia; Vol. 58 Núm. 2 (2012): abr./mayo/jun.; 251-255 Revista Brasileira de Cancerologia; v. 58 n. 2 (2012): abr./maio/jun. ; 251-255 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042244695359488 |